KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $1.4 billion.

  • AbCellera Biologics' Liabilities and Shareholders Equity fell 2.64% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 billion, marking a year-over-year decrease of 5.10%. This contributed to the annual value of $1.4 billion for FY2024, which is 8.57% down from last year.
  • As of Q3 2025, AbCellera Biologics' Liabilities and Shareholders Equity stood at $1.4 billion, which was down 3.29% from $1.4 billion recorded in Q2 2025.
  • AbCellera Biologics' 5-year Liabilities and Shareholders Equity high stood at $1.6 billion for Q2 2022, and its period low was $1.1 billion during Q1 2021.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.4 billion, with a median of $1.4 billion in 2024.
  • In the last 5 years, AbCellera Biologics' Liabilities and Shareholders Equity surged by 41.09% in 2022 and then fell by 8.57% in 2024.
  • AbCellera Biologics' Liabilities and Shareholders Equity (Quarterly) stood at $1.3 billion in 2021, then climbed by 16.86% to $1.5 billion in 2022, then decreased by 3.43% to $1.5 billion in 2023, then decreased by 8.57% to $1.4 billion in 2024, then declined by 2.64% to $1.4 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.4 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.3 billion in Q1 2025.